TEL AVIV, Israel, Aug. 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced financial results for the three and six months ended June 30, 2017 and provided a corporate update.
“VBL made significant advances on clinical and operational fronts during the second quarter of 2017,” said Prof. Dror Harats, Chief Executive Officer of VBL Therapeutics. “We continue to progress in our Phase 3 GLOBE study investigating our lead asset VB-111 in patients with recurrent glioblastoma (rGBM). The trial is proceeding according to plan, following a second positive review by the independent Data Safety Monitoring Committee (DSMC) that took place in April. We expect a final DSMC review in late September, and top-line data in Q1 2018. Based on our interactions with the FDA and the SPA for the trial, the GLOBE study should support a Biologics License Application (BLA)."
“VBL made significant advances on clinical and operational fronts during the second quarter of 2017,” said Prof. Dror Harats, Chief Executive Officer of VBL Therapeutics. “We continue to progress in our Phase 3 GLOBE study investigating our lead asset VB-111 in patients with recurrent glioblastoma (rGBM). The trial is proceeding according to plan, following a second positive review by the independent Data Safety Monitoring Committee (DSMC) that took place in April. We expect a final DSMC review in late September, and top-line data in Q1 2018. Based on our interactions with the FDA and the SPA for the trial, the GLOBE study should support a Biologics License Application (BLA)."
